Compare · BVS vs MDLN
BVS vs MDLN
Side-by-side comparison of Bioventus Inc. (BVS) and Medline Inc. (MDLN): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both BVS and MDLN operate in Medical/Dental Instruments (Health Care), so they compete in similar markets.
- MDLN is the larger of the two at $46.86B, about 39.6x BVS ($1.18B).
- MDLN has been more active in the news (12 items in the past 4 weeks vs 2 for BVS).
- MDLN has more recent analyst coverage (25 ratings vs 14 for BVS).
- Company
- Bioventus Inc.
- Medline Inc.
- Price
- -
- -
- Market cap
- $1.18B
- $46.86B
- 1M return
- -
- -
- 1Y return
- -
- -
- Industry
- Medical/Dental Instruments
- Medical/Dental Instruments
- Exchange
- NASDAQ
- NASDAQ
- IPO
- 2021
- 2025
- News (4w)
- 2
- 12
- Recent ratings
- 14
- 25
Bioventus Inc.
Bioventus Inc. a medical device company, focuses on developing and commercializing clinically treatments that engage and enhance the body's natural healing process in the United States and internationally. The company provides osteoarthritic joint pain treatment and joint preservation products, including Durolane, a single injection therapy; GELSYN-3, a three injection therapy; and SUPARTZ FX, a five injection therapy. It also offers bone graft substitutes comprising allograft-derived bone graft with growth factors, demineralized bone matrix, cancellous bone in different preparations, bioactive synthetics, collagen ceramic matrix, and bone marrow isolation systems. In addition, the company provides Exogen systems for the non-invasive treatment of established nonunion fractures and certain fresh fractures. It serves physicians spanning the orthopedic continuum, including sports medicine, total joint reconstruction, hand and upper extremities, foot and ankle, podiatric surgery, trauma, spine, and neurosurgery in the physician's office or clinic, ambulatory surgical centers, or in the hospital setting. The company was founded in 2011 and is headquartered in Durham, North Carolina.
Latest BVS
- SEC Form 10-Q filed by Bioventus Inc.
- Bioventus Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Other Events, Financial Statements and Exhibits
- Bioventus to Report Second Quarter of Fiscal Year 2026 Financial Results on August 5, 2026
- Director Bartholdson John A. converted options into 32,282 shares, increasing direct ownership by 41% to 111,902 units (SEC Form 4)
- Director Sutter Martin P converted options into 32,282 shares, increasing direct ownership by 38% to 117,523 units (SEC Form 4)
- Director Stalnecker Susan M converted options into 32,282 shares, increasing direct ownership by 30% to 138,239 units (SEC Form 4)
- Director Nohra Guy P converted options into 32,282 shares, increasing direct ownership by 28% to 148,892 units (SEC Form 4)
- Director Neels Guido J converted options into 32,282 shares, increasing direct ownership by 38% to 117,523 units (SEC Form 4)
- Director Hawkins William A converted options into 39,789 shares, increasing direct ownership by 15% to 297,640 units (SEC Form 4)
- Director Ladone Mary Kay converted options into 32,282 shares, increasing direct ownership by 41% to 111,263 units (SEC Form 4)
Latest MDLN
- SEC Form 4 filed by Chief Executive Officer Boyle James M
- SEC Form 4 filed by Chief Operating Officer Miller Stephen L
- Large owner Gic Private Ltd sold $57,280,000 worth of shares (1,600,000 units at $35.80) (SEC Form 4)
- Amendment: SEC Form SCHEDULE 13G/A filed by Medline Inc.
- Large owner Gic Private Ltd sold $21,002,305 worth of shares (590,284 units at $35.58) (SEC Form 4)
- Large owner Mozart Holdco, Inc. converted options into 500,000 shares and disposed of 500,000 units of Class B Common Stock, increasing direct ownership by 81,083% to 233,520,656 units (SEC Form 4)
- Amendment: SEC Form SCHEDULE 13G/A filed by Medline Inc.
- Large owner Gic Private Ltd sold $79,971,448 worth of shares (2,248,612 units at $35.56) (SEC Form 4)
- SEC Form SCHEDULE 13G filed by Medline Inc.
- SEC Form 10-Q filed by Medline Inc.